All Releases
 |
Enzon Reports Second Quarter 2010 Results
Aug 3, 2010
|
22.6 KB |
|
| |
BRIDGEWATER, N.J., Aug 03, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial
results for the second quarter of 2010. For the second quarter of 2010,
Enzon reported a loss from continuing operations of $5.4 million or
$0.09 per diluted share, as compared to a loss of $19.7 millio...
|
|
Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow
Jul 28, 2010
|
7.8 KB |
|
| |
BRIDGEWATER, N.J., Jul 28, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will
report its financial results for the quarter ended June 30, 2010, on
Tuesday, August 3, 2010 at 4:00 pm Eastern Time (ET). The release will
be followed by a live conference call, which will begin at 5:00...
|
|
Enzon Reports 1st Quarter 2010 Results
May 10, 2010
|
25.1 KB |
|
| |
BRIDGEWATER, N.J., May 10, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial
results for the first quarter of 2010. During the quarter, the Company
completed the sale of its specialty pharmaceutical business. This
transaction has now transformed the Company, both financially and...
|
|
Enzon Sets Date of 2010 Annual Meeting
May 7, 2010
|
5.7 KB |
|
| |
BRIDGEWATER, N.J., May 07, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") today announced
that it has set Tuesday, July 13, 2010 as the date of its 2010 Annual
Meeting of Stockholders (the "Annual Meeting"), and that the record date
for determining stockholders entitled to vote at the Annual Mee...
|
|
Enzon to Release First Quarter 2010 Earnings on Monday, May 10, 2010; Conference Call and Webcast to Follow
May 6, 2010
|
6.9 KB |
|
| |
BRIDGEWATER, N.J., May 06, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will
report its financial results for the quarter ended March 31, 2010, on
Monday, May 10, 2010 at approximately 8:00 am Eastern Time (ET). The
release will be followed by a live conference call, which will b...
|
|
Enzon to Enhance Governance by Eliminating Board Classes
Apr 22, 2010
|
12.7 KB |
|
| |
BRIDGEWATER, N.J., Apr 22, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that its
Board of Directors has approved amendments to the Company's certificate
of incorporation and bylaws that will declassify the Board of Directors
so that all directors will be elected annually. If approved by ...
|
|
Enzon Presents Data at 2010 AACR Meeting
Apr 21, 2010
|
12.0 KB |
|
| |
BRIDGEWATER, N.J., Apr 21, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its
pipeline programs at the 2010 AACR (American Association for Cancer
Research) annual meeting in Washington, DC.
"We are pleased to present new data from our novel pipeline programs.
Our Customized PEG linker...
|
|
Enzon Will Present New Data on LNA and PEGylation Programs
Apr 13, 2010
|
8.8 KB |
|
| |
BRIDGEWATER, N.J., Apr 13, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new data will
be presented on Locked Nucleic Acid (LNA) based antisense
oligonucleotide programs directed against, the androgen receptor (AR),
hedgehog pathway GLI2, and beta-catenin. The Company will also present
...
|
|
Enzon's Debt is Reduced by $116 Million
Mar 8, 2010
|
7.3 KB |
|
| |
BRIDGEWATER, N.J., Mar 08, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the results
from the recent tender and increased conversion periods of the 4 percent
convertible notes due in 2013. As a result of the sale of the specialty
pharmaceutical business on January 29, 2010, the Company wa...
|
|
Enzon Opens Pediatric Study of PEG-SN38
Feb 24, 2010
|
7.9 KB |
|
| |
BRIDGEWATER, N.J., Feb 24, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the
first patient has been treated in the Phase 1 study of PEG-SN38 for
pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated
form of SN38, the active metabolite of the cancer drug Camptosar(R)
...
|
|
Enzon Board of Directors Appoints Executive Committee
Feb 22, 2010
|
7.1 KB |
|
| |
BRIDGEWATER, N.J., Feb 22, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Jeffrey
Buchalter has resigned as Chief Executive Officer and Director of Enzon,
effective immediately, and has been replaced by a newly formed executive
committee of the Board. This new committee will be chaire...
|
|
Enzon Reports 2009 Results
Feb 17, 2010
|
27.0 KB |
|
| |
BRIDGEWATER, N.J., Feb 17, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial
results for 2009. For the three months ended December 31, 2009, Enzon
reported a net loss of $0.2 million or breakeven per diluted share, as
compared to a net loss of $0.5 million or $0.01 per diluted s...
|
|
CORRECTING and REPLACING Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
Feb 9, 2010
|
7.1 KB |
|
| |
BRIDGEWATER, N.J., Feb 09, 2010 (BUSINESS WIRE) -- Second graph, first sentence of release should read: Participating in
the call from Enzon's executive management team will be Jeffrey H.
Buchalter, President and Chief Executive Officer ... (sted: Chairman
and Chief Executive Officer).
The corrected release reads:
ENZON TO...
|
|
Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
Feb 9, 2010
|
6.9 KB |
|
| |
BRIDGEWATER, N.J., Feb 09, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will
report its financial results for the quarter ended December 31, 2009, on
Wednesday, February 17, 2010 at approximately 8:00 am Eastern Time (ET).
The release will be followed by a live conference call, w...
|
|
Enzon Completes Sale of Specialty Pharmaceutical Business
Jan 29, 2010
|
9.0 KB |
|
| |
BRIDGEWATER, N.J., Jan 29, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced today
that it has closed the sale of its specialty pharmaceutical business to
the sigma-tau Group ("sigma-tau"). Enzon is a biopharmaceutical company
dedicated to the discovery and development of important medici...
|
|
Enzon Stockholders Approve Sale of Specialty Pharmaceutical Business
Jan 27, 2010
|
7.1 KB |
|
| |
BRIDGEWATER, N.J., Jan 27, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced that at a
special meeting held this morning, its stockholders approved the sale of
Enzon's specialty pharmaceutical business to the sigma-tau Group
("sigma-tau").
Enzon's specialty pharmaceutical business includ...
|
|
Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
Jan 6, 2010
|
8.2 KB |
|
| |
BRIDGEWATER, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the
first patient has been treated in the Phase 2 studies of PEG-SN38 for
metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon's PEGylated form
of SN38, the active metabolite of the cancer drug Camptosar(R)
...
|
|
Enzon Sets Date of Special Meeting of Stockholders to Approve Sale of Specialty Pharmaceutical Business
Dec 22, 2009
|
8.4 KB |
|
| |
BRIDGEWATER, N.J., Dec 22, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced today
that it has set Wednesday, January 27, 2010 as the date of the special
meeting of stockholders to vote on the proposed sale of its specialty
pharmaceutical business to the sigma-tau Group. Stockholders of r...
|
|
Enzon Board Authorizes Share Repurchase of up to $50 Million
Dec 3, 2009
|
7.7 KB |
|
| |
BRIDGEWATER, N.J., Dec 03, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that its
Board of Directors has authorized the repurchase of up to $50 million of
its outstanding shares of common stock in order to return value to its
shareholders.
The share repurchase program will be funded from...
|
|
Enzon Presents Data at 2009 EORTC Meeting
Nov 19, 2009
|
13.3 KB |
|
| |
BRIDGEWATER, N.J., Nov 19, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its
pipeline programs at the 2009 EORTC-NCI-AACR (European Organization for
Research and Treatment of Cancer-National Cancer Institute-American
Association for Cancer Research) annual meeting in Boston, Massachus...
|
|
|
0.17
